Dr. Baher Daihom, Assistant Professor at the College of Pharmacy, American University of Iraq–Baghdad, continues his distinguished research journey that has positioned him among the leading scientists in the region in the field of 3D printing–based drug therapy. Recently, a high-impact Q1 scientific journal published by Springer Nature Link released a research article titled “3D-printed Gabapentin-loaded Implants for Sustained Release: Leveraging 3D Printing and Hot Melt Extrusion (HME) for Customizable Drug Delivery”, with Dr. Daihom as the lead author.
The study focuses on the development of innovative drug implants fabricated using 3D printing technology and loaded with gabapentin, a medication commonly used for neuropathic pain. These implants are designed to be placed subcutaneously to provide controlled and sustained drug release over an extended period. The research was conducted in collaboration with The University of Texas at Austin and several other international institutions, reflecting AUIB’s strong commitment to building global research partnerships and advancing innovative therapeutic technologies that serve the future of healthcare in Iraq and the region.
As part of his ongoing international academic activity, Dr. Daihom recently delivered an invited lecture at the Saudi Heart Association Annual Conference in the Kingdom of Saudi Arabia, titled “Enhancing Therapeutic Outcomes in Cardiovascular Diseases Using 3D Printing Technologies.” His presentation highlighted cutting-edge approaches in personalized drug and device design, including bioresorbable 3D-printed stents and targeted drug delivery systems for cardiovascular therapy. He emphasized the potential of 3D printing to improve treatment efficacy and minimize side effects, paving the way toward a new era of personalized cardiovascular medicine.
This achievement comes as part of a sustained record of scientific excellence and global engagement. Dr. Daihom previously presented an oral talk at the International Pharmaceutical Federation (FIP) World Congress held in Cape Town, South Africa, where his work on 3D printing applications for bone cancer therapy received significant attention from the scientific community.
Dr. Daihom believes that 3D printing represents a true revolution in pharmaceutical sciences, enabling the design of customized dosage forms tailored to each patient’s specific needs—enhancing precision, safety, and efficacy. By integrating this technology with artificial intelligence, the future of pharmacy will move toward smart, personalized, and more effective treatments, reshaping the landscape of modern drug therapy in the coming decade.
“I am proud to place the name of the American University of Iraq–Baghdad at the forefront of global scientific research. This achievement sends a clear message that our university is capable of competing, innovating, and contributing to shaping the future of medical sciences,” said Dr. Baher Daihom.
Dr. Daihom has 20 years of experience in teaching and academic research across leading international and regional universities. He is also a Fulbright Alumnus from The University of Texas at Austin, USA. His research interests include drug delivery systems, 3D printing in pharmaceutics, and smart drug release technologies, in addition to supervising innovative research projects that contribute to advancing pharmaceutical education and scientific research in Iraq and the broader region.